Hypereosinophilia: A Guideline for Workup in the Allergy Community

Authors

  • Joshua O’Connell, MBBS
  • Michael Trus, MD, PhD

DOI:

https://doi.org/10.58931/cait.2022.2232

Abstract

Determining the etiology of eosinophilia, defined as an absolute eosinophil count (AEC) greater than 500 cells/µL, is often difficult given the many potential causes spanning several medical specialties. The diagnosis becomes more urgent in the case of hypereosinophilia (≥1,500 cells/µL) due to concerns over potential end organ damage. The goal of this review is to educate physicians about the biology, etiologies, and workup of hypereosinophilia.

Author Biographies

Joshua O’Connell, MBBS

Dr. Joshua O’Connell is a clinic manager and physician assistant for a family practice in Toronto, Ontario. He received his medical degree from St. George’s University of London, England and completed a post-doctoral research fellowship with a focus on pediatric surgery and stem cell research at The Hospital for Sick Children in Toronto, Ontario.

Michael Trus, MD, PhD

Dr. Michael Trus received his MD degree from Dalhousie University and completed residencies in internal medicine and hematology in Ottawa, Ontario. He completed his PhD studies in the field of epigenetic regulation of acute myelogenous leukemia at the Princess Margaret Hospital in Toronto, Ontario. Dr. Trus currently works in Hamilton, Ontario where he specializes in the treatment of malignant hematological diseases and allogeneic stem cell transplantation. His practice also focuses on the treatment of patients with eosinophilic and mast cell disorders. Dr. Trus serves as the Co-Director of the Eosinophilic Lung Disorders clinic at St. Joseph’s Hospital, Hamilton, ON along with Dr. P. Nair.

References

Chusid MJ, Dale DC, West BC, Wolff SM. The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine. 1975 Jan;54(1):1-27.

Ramirez GA, Yacoub MR, Ripa M, et al. Eosinophils from Physiology to Disease: A Comprehensive Review. BioMed research international. 2018;2018:9095275. doi:10.1155/2018/9095275

Akuthota P, Weller PF. Spectrum of Eosinophilic End-Organ Manifestations. Immunol Allergy Clin North Am. 2015;35(3):403-411. doi:10.1016/j.iac.2015.04.002

Magnaval J-F, Laurent G, Gaudré N, Fillaux J, Berry A. A diagnostic protocol designed for determining allergic causes in patients with blood eosinophilia. Military Medical Research. 2017 May 23;4(1):15. doi:10.1186/s40779-017-0124-7

Nelson RK, Bush A, Stokes J, Nair P, Akuthota P. Eosinophilic Asthma. J Allergy Clin Immunol: In practice. 2020 Feb;8(2):465-473. doi:10.1016/j.jaip.2019.11.024

Burris D, Rosenberg CE, Schwartz JT, et al. Pediatric Hypereosinophilia: Characteristics, Clinical Manifestations, and Diagnoses. J Allergy Clin Immunol: In practice. 2019 Nov-Dec;7(8):2750-2758.e2. doi:10.1016/j.jaip.2019.05.011

Leverone N, Tran S, Barry J, Akuthota P. Diagnoses associated with peripheral blood eosinophilia: A 5-year review. Ann Allergy Asthma Immunol. 2021;127(5):597-598. doi:10.1016/j.anai.2021.08.013

Fujieda S, Imoto Y, Kato Y, et al. Eosinophilic chronic rhinosinusitis. Allergology international : official journal of the Japanese Society of Allergology. 2019 Oct;68(4):403-412. doi:10.1016/j.alit.2019.07.002

Reiter A, Gotlib J. Myeloid neoplasms with eosinophilia. Blood. 2017 Feb 9;129(6):704-714. doi:10.1182/blood-2016-10-695973

Butt NM, Lambert J, Ali S, et al. Guideline for the investigation and management of eosinophilia. Br J Haematol. 2017;176(4):553-572. doi:10.1111/bjh.14488

Roufosse F, Weller PF. Practical approach to the patient with hypereosinophilia. J Allergy Clin Immunol. 2010;126(1):39-44. doi:10.1016/j.jaci.2010.04.011

Stauffer WM, Alpern JD, Walker PF. COVID-19 and Dexamethasone: A Potential Strategy to Avoid Steroid-Related Strongyloides Hyperinfection. JAMA. 2020;324(7):623-624. doi:10.1001/jama.2020.13170

Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and Exacerbations of Refractory Eosinophilic Asthma. N Engl J Med. 2009;360(10):973-984. doi:10.1056/NEJMoa0808991

Nair P, Pizzichini MM, Kjarsgaard M, et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med. 2009 Mar 5;360(10):985-93. doi:10.1056/NEJMoa0805435

Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016 May 19;127(20):2391-405. doi:10.1182/blood-2016-03-643544

Ault P, Cortes J, Koller C, Kaled ES, Kantarjian H. Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate. Leuk Res. 2002 Sep;26(9):881-4. doi:10.1016/s0145-2126(02)00046-2

Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003 Mar 27;348(13):1201-14. doi:10.1056/NEJMoa025217

Gleich GJ, Leiferman KM, Pardanani A, Tefferi A, Butterfield JH. Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet. 2002 May 4;359(9317):1577-8. doi:10.1016/s0140-6736(02)08505-7

Schaller JL, Burkland GA. Case report: rapid and complete control of idiopathic hypereosinophilia with imatinib mesylate. MedGenMed: Medscape general medicine. 2001 Sep 7;3(5):9.

Stover EH, Chen J, Lee BH, et al. The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo. Blood. 2005;106(9):3206-3213. doi:10.1182/blood-2005-05-1932

Nair P, Ochkur SI, Protheroe C, Simms E, Lee NA, Lee JJ. The identification of eosinophilic gastroenteritis in prednisone-dependent eosinophilic bronchitis and asthma. Allergy, Asthma & Clinical Immunology. 2011 Mar 1;7(1):4. doi:10.1186/1710-1492-7-4

Gioffredi A, Maritati F, Oliva E, Buzio C. Eosinophilic granulomatosis with polyangiitis: an overview. Front Immunol. 2014;5:549-549. doi:10.3389/fimmu.2014.00549

Bel EH, Wenzel SE, Thompson PJ, et al. Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma. New England Journal of Medicine. 2014;371(13):1189-1197. doi:10.1056/NEJMoa1403291

Betancor D, Plaza KL, Eguez JC, Nair P, Trus M. Exon 8 KIT mutation and pulmonary eosinophilia. Allergy. 2020;75(8):2094-2096. doi:10.1111/all.14272

Downloads

Published

2022-07-01

How to Cite

1.
O’Connell J, Trus M. Hypereosinophilia: A Guideline for Workup in the Allergy Community. Can Allergy Immunol Today [Internet]. 2022 Jul. 1 [cited 2024 Nov. 21];2(2):20–23. Available from: https://canadianallergyandimmunologytoday.com/article/view/2-2-oconnell_et_al

Issue

Volume 2, Issue 2, July 2022

Section

Articles